These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 16819434)

  • 1. Myeloablative conditioning for hematopoietic stem-cell transplantation in patients with non-malignant diseases.
    Ringdén O; Svenberg P; Le Blanc K; Mattsson J; Remberger M
    Bone Marrow Transplant; 2006 Aug; 38(4):321-2. PubMed ID: 16819434
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens.
    Burt RK; Marmont A; Oyama Y; Slavin S; Arnold R; Hiepe F; Fassas A; Snowden J; Schuening F; Myint H; Patel DD; Collier D; Heslop H; Krance R; Statkute L; Verda L; Traynor A; Kozak T; Hintzen RQ; Rose JW; Voltarelli J; Loh Y; Territo M; Cohen BA; Craig RM; Varga J; Barr WG
    Arthritis Rheum; 2006 Dec; 54(12):3750-60. PubMed ID: 17133541
    [No Abstract]   [Full Text] [Related]  

  • 3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is reduced-intensity conditioning the standard of care in the transplant setting?
    Giralt SA
    Clin Adv Hematol Oncol; 2008 May; 6(5):337-9. PubMed ID: 18516022
    [No Abstract]   [Full Text] [Related]  

  • 5. Myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for childhood central nervous system tumors.
    Marachelian A; Butturini A; Finlay J
    Bone Marrow Transplant; 2008 Jan; 41(2):167-72. PubMed ID: 18176620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.
    Craddock CF
    Bone Marrow Transplant; 2008 Mar; 41(5):415-23. PubMed ID: 18209726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safe administration of oral BU twice daily during conditioning for stem cell transplantation in a paediatric population: a comparative study between the standard 4-dose and a 2-dose regimen.
    Mellgren K; Nilsson C; Fasth A; Abrahamsson J; Winiarski J; Ringdén O; Hassan M
    Bone Marrow Transplant; 2008 Apr; 41(7):621-5. PubMed ID: 18084338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesenchymal stem cells remain host-derived independent of the source of the stem-cell graft and conditioning regimen used.
    Bartsch K; Al-Ali H; Reinhardt A; Franke C; Hudecek M; Kamprad M; Tschiedel S; Cross M; Niederwieser D; Gentilini C
    Transplantation; 2009 Jan; 87(2):217-21. PubMed ID: 19155975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematopoietic stem cell transplantation in childhood inherited bone marrow failure syndrome.
    Gluckman E; Wagner JE
    Bone Marrow Transplant; 2008 Jan; 41(2):127-32. PubMed ID: 18084332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic haematopoietic stem cell transplant in Philadelphia-positive acute lymphoblastic leukaemia.
    Fielding AK; Goldstone AH
    Bone Marrow Transplant; 2008 Mar; 41(5):447-53. PubMed ID: 17968326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
    Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Quigley J; Chen YH; Mahmud N; Hurter E; Beri R; Rondelli D
    Bone Marrow Transplant; 2008 Jun; 41(11):935-40. PubMed ID: 18264144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome after bone marrow transplantation for aplastic anemia using cyclophosphamide and total lymphoid irradiation as conditioning regimen.
    Inamoto Y; Suzuki R; Kuwatsuka Y; Yasuda T; Takahashi T; Tsujimura A; Sugimoto K; Oba T; Terakura S; Atsuta Y; Murata M; Ito M; Kodera Y; Miyamura K
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):43-9. PubMed ID: 18158960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
    Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Chen HY; Mahmud N; Quigley J; Hoffman R; Jessop E; Beri R; Rondelli D
    Bone Marrow Transplant; 2006 Oct; 38(7):477-82. PubMed ID: 16980995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
    Bartelink IH; Bredius RG; Ververs TT; Raphael MF; van Kesteren C; Bierings M; Rademaker CM; den Hartigh J; Uiterwaal CS; Zwaveling J; Boelens JJ
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):88-98. PubMed ID: 18158965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience.
    Mori T; Aisa Y; Yokoyama A; Nakazato T; Yamazaki R; Shimizu T; Mihara A; Kato J; Watanabe R; Takayama N; Ikeda Y; Okamoto S
    Bone Marrow Transplant; 2007 Feb; 39(4):217-21. PubMed ID: 17220902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A myeloablative conditioning regimen for patients with impaired cardiac function undergoing allogeneic stem cell transplantation: reduced cyclophosphamide combined with etoposide and total body irradiation.
    Yoshimi A; Nannya Y; Sakata-Yanagimoto M; Oshima K; Takahashi T; Kanda Y; Motokura T; Chiba S; Kurokawa M
    Am J Hematol; 2008 Aug; 83(8):635-9. PubMed ID: 18506704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
    Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
    Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allografting or autografting for myeloma.
    Rajkumar SV; Kyle RA
    N Engl J Med; 2007 Jun; 356(25):2646-8; author reply 2646-8. PubMed ID: 17600891
    [No Abstract]   [Full Text] [Related]  

  • 20. Allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia following nonmyeloablative conditioning using 200-cGy total body irradiation and fludarabine.
    Koh LP; Koh MB; Ng HY; Hwang WY; Goh YT; Linn YC; Ng HJ; Chuah CT; Tan KW; Loh YS; Tan DC; Tan PH; Tan PH
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):887-90. PubMed ID: 16864060
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.